ISSN: 2155-6105

Journal de recherche et de thérapie en toxicomanie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Indexé dans
  • Indice source CAS (CASSI)
  • Index Copernic
  • Google Scholar
  • Sherpa Roméo
  • Ouvrir la porte J
  • JournalSeek de génamique
  • Clés académiques
  • JournalTOC
  • SécuritéLit
  • Infrastructure nationale du savoir de Chine (CNKI)
  • Bibliothèque de revues électroniques
  • Recherche de référence
  • Université Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catalogue en ligne SWB
  • Bibliothèque virtuelle de biologie (vifabio)
  • Publons
  • Fondation genevoise pour l'enseignement et la recherche médicale
  • Euro Pub
  • ICMJE
Partager cette page

Abstrait

A Descriptive Review of Hyperbaric Oxygen Therapy in the Management of Substance Use Disorders

Peter McCann and Margaret-Ann McCann

Background and aim: Psychological therapies and some limited pharmacotherapy forms the mainstay of treatment for substance use disorders. However despite extensive research little progress has been made into developing therapies to aid in the initial detoxification phase, the maintenance of remission and to treat the morbidity associated with many drugs of abuse. The following review explores the use of hyperbaric oxygen therapy as an adjunctive treatment for some of the harmful aspects of exposure to alcohol, cocaine and opioids. Method: We conducted a systematic review of articles searched through PubMed for the use of HBOT for conditions related to alcohol, cocaine and opioid use disorders. Outcome measures included improvement in neurocognitive functioning, improvement in withdrawal symptoms and improved sleep and quality of life. Results: Few studies directly investigated the use of HBOT for complications of substance use in humans however several studies were found that looked at conditions with shared features including traumatic brain injury, vascular dementia and chronic pain. Conclusion: There is a lack of human studies assessing the impact of HBOT on sequelae of substance use however findings from animal studies and use of HBOT in related conditions show that there is potential for this therapy in the management of withdrawal syndromes, neurocognitive deficits and quality of life.